Podcasts about boston children

Fundraising is commonly portrayed as challenging, but for mission-driven leaders, it's also a privilege because they've got to be one of the helpers in this time period. In this episode, Dana Smiley joins Mallory to discuss donor stewardship through the lens of authenticity, purpose, and human connection. Join us as our guest dives into the exhaustion that comes with the role, the mindset shift that keeps teams grounded, and the power of transparent, genuine interactions.  Hilary Dana Smiley is a seasoned, result-driven fund development professional and currently the Assistant Vice President of Leadership Gifts at Boston Children's Hospital, where she oversees individual giving, direct response efforts, face-to-face fundraising, and volunteer board engagement. She leads with a genuine passion and purpose, believing in authentic enthusiasm strengthening donor relationships and fueling the mission of caring for children and families. In this episode, you will be able to: Learn how reconnecting with your purpose elevates donor communication. Understand the role of authenticity and passion in long-term donor relationships. Acquire new ways in navigating exhaustion and reframe hard fundraising moments. How to inspire generosity with transparent, human-centered communication.  Learn practices that strengthen stewardship and keep teams grounded in mission. Get all the resources from today's episode here.  Support for this show is brought to you by Practivated. Practivated delivers AI-powered donor conversation simulations that let fundraisers practice in a private, judgment‑free space—building confidence, refining messaging, and improving outcomes before the real conversation even begins. Developed by fundraising experts with real‑time coaching at its core, it's the smart way to walk into every donor interaction calm, prepared, and ready to connect. Learn more at practivated.com Connect with me:  Instagram: https://www.instagram.com/_malloryerickson/ Facebook: https://www.facebook.com/whatthefundraising YouTube: https://www.youtube.com/@malloryerickson7946 LinkedIn: https://www.linkedin.com/mallory-erickson-bressler/ Website: malloryerickson.com/podcast Loved this episode? Leave us a review and rating here: https://podcasts.apple.com/us/podcast/what-the-fundraising/id1575421652 If you haven't already, please visit our new What the Fundraising community forum. Check it out and join the conversation at this link. If you're looking to raise more from the right funders, then you'll want to check out my Power Partners Formula, a step-by-step approach to identifying the optimal partners for your organization. This free masterclass offers a great starting point.

In this episode of The World of Wishes Podcast we meet wish alumnus Lauren Potter. A top junior Olympian at 13, Lauren was a relentless competitor—until a rare, unnamed autoimmune disease left her gasping for breath. After months in Boston Children's Hospital and six rounds of chemotherapy, she chose hope over fear. When her doctor recommended Make‑A‑Wish, Lauren celebrated her recovery with an active, adventurous wish: surfing her first wave on Waikiki Beach, ATV trails through Kualoa Ranch, ziplining across thousand‑foot valleys, and a sunset on the North Shore that felt like peace. Years later, she committed to Yale volleyball, mentored other pulmonary patients, thanked her wish sponsors from the stage, and found her career intersecting with our Miami home—the Finker‑Frenkel Wish House—bringing her journey full circle. In this episode, Lauren shares how positivity, family, and a single wish can fuel a decade of momentum—and why she proudly wears “Wish Kid” as a badge of honor. Learn more about how can get involved at https://wish.org/sfla!Be sure to follow us @makeawishsfla on Instagram, Facebook, YouTube, Twitter, TikTok, and LinkedIn!Subscribe, Rate, & Review this podcast to support future episodes that will feature wish kids and parents' past and present, volunteers, donors, referral sources and everyone who contributes to this World of Wishes!

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USADoctors Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at the MDA 2025 conference in Dallas, Texas, in March 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established. In contents of this podcast, shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The ASPIRO clinical trial is on clinical hold since September 2021.In this part, Doctor Beggs will provide an explanation of AAV-mediated gene therapies.Alan Beggs, PhDAAV vectors, which I'm going to be talking about more today, or Adeno associated viral vectors are small viruses. Their DNA gets delivered into the cell and remains extrachromosomal. There are very rare occasional integrations, but the risk of oncogenesis as a result is significantly lower as a consequence of remaining extrachromosomal, though, we do have to think about what happens as the cells divide and potentially the durability of treatment is more limited.There have been a lot of movement and development over the years, starting back in the 1980s when the first AAV genomes were isolated and sequenced. This led to a development of methods to produce recombinant AAVs that would lack the genes necessary for viral replication, but contain a therapeutic gene you wish to deliver. Through this, the structure of AAVs have been developed. There have been isolation of a number of naturally occurring variants. You've heard of AAV8, AAV9, also RH 74, derived from a rhesus monkey for the RH. These have all been used in clinical trials. Then at the end I'll talk a little bit about directed evolution methods to actually engineer capsids with particular properties that are beneficial.Throughout this we've identified some of the issues that arise in this. It was initially thought that AAV vectors were non-immunogenic, but in fact there are immune responses not just to the viral payload to the therapeutic protein, but also to the viral vectors, and you're going to hear about that from Doctor Parsons. Over time, as we've come to understand these challenges, we've also been developing approaches to mitigate them. In terms of clinical trials and treatments, the very first studies were done back in the 1970s.By the early 2000, the very first clinical therapeutic was approved in China. It was actually an oncolytic virus carrying a p53 gene to treat head and neck cancers. By now there are over 40 approved treatments for various types of AAV delivered gene therapies. Of course, the ones we know a lot about are Zolgensma, which was approved in 2019, and Elevidys, which was approved last year. A number of challenges and then also a number of approaches to overcome those challenges. First of all, the preclinical data are not always sufficient to predict the response of a human patient.For example, in X-linked myotubular myopathy we had mouse and dog models that exhibited a myopathy but nothing else, and yet when we treated human patients, we discovered that patients with X-linked myotubular myopathy actually had a previously only poorly recognized hepatopathology that led to potential liver consequences following gene therapy. The animal models don't always predict the clinical outcome in humans.Also, we have small disease populations. These are rare diseases. It's important to understand the natural history of these diseases, understand the heterogeneity among the clinical population. It's very important to engage with families and with patients and communities, understand who might be at increased risk to treatment with one of these. This feeds into safety considerations. We need to think also about some of the immune responses. I think we're starting to learn, for example, with the gene therapies for Duchenne, and we know this from SMA that some patients get into trouble and others don't. We need to understand why that may be, and we don't know about the long term effects. This has been very recent.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USAThe challenges that you've heard about are real. Some of them I think we could have foreseen others. There was no way to know until we actually started treating patients in clinic. But we now know that there are immune responses and also responses just to the viral load. As Julie mentioned, we're giving massive doses to these patients on the order of one times ten to the 14 viral genomes per kilogram.Think about the fact that when these capsids are manufactured, there's a certain percentage of empty capsid. The amount of protein that's being delivered to these patients can be massive. One of the approaches to mitigate some of the risk would be to lower the dose. While early studies demonstrated that in order to get adequate delivery to skeletal muscle, you need to give these very large doses. But what if we could engineer a viral capsid that would be potent at lower doses?There has been quite a bit of research in this area that's ongoing, and some new next generation vectors that are just starting to enter the clinic. In particular, there are a class of Myotropic viral vectors or capsids so-called RGD vectors. RGD refers to arginine, glycine, and aspartic acid, which are three residues which, when present at a particular point in the viral capsid proteins interact with integrin receptors that are specific for skeletal muscle. These viral capsids home to skeletal muscle and can deliver their genetic payload at much lower doses. There was one group of these developed in Germany by Theo Grimm's lab.These were the so-called AAV Myos, and simultaneously in Boston at the Broad Institute, a group of capsids was developed that were called Myo AAV. These were both based off of an AAV nine backbone. It's basically an AAV nine legacy vector with these three amino acids changed. Now Solid Biosciences also has their own independently derived vector that I believe is also an RGD vector. These vectors give us the potential then for more efficient and specific delivery to muscle cells.They may or may not target the liver depending on the particular virus. Some of them the risk to the liver is mitigated by delivering a lower dose. You can also develop these vectors in a way that will be liver targeted, that specifically less of it gets delivered to the vectors. These would be really, in my mind potentially third generation vectors.Strategies, there are a number of strategies. You heard about the immunomodulation regimens. I just talked about optimizing vector design. Also, Doctor Parsons mentioned earlier the fact that where you deliver so zolgensma is delivered Intrathecally. We get it to the place we need it, and we're less likely to have off target effects through other tissues.Then improved manufacturing is very important. I mentioned the fact that every viral preparation contains empty capsids. There are ways to minimize the production of empty capsids, and also effective ways to filter out and remove those empty capsids. This is actually a very important aspect that is being developed further by the CMO community. Then in summary, I think it's important to take a holistic approach when we're thinking about the development of AAV based gene therapies for neuromuscular disease.It starts from the fact that for any given disease we're interested in, we need to define the genetic etiology. Since these are gene directed therapies. We need to pay careful attention to the preclinical animal models. How accurately do they really reflect the human condition? Or are there potentially responses in our human patients that we haven't experienced in the animals? It's important to understand the natural history and the patient population.Recognize that there's extensive heterogeneity, not just in age and severity, but also potentially in underlying susceptibilities in our patients. We have a group of toxicities that we know about and can anticipate. But as Julie was saying, you need to be really careful and think about any potential unexpected SAEs. And then finally I mentioned the manufacturing aspect, the development of newer vectors and quality control aspects that go into making a safe and effective therapeutic.In the next part. Doctor Parsons will discuss clinical safety and efficacy observed in AAV mediated gene therapy programs in DMD, SMA, and XLMTM.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe ASPIRO Clinical Trial is on clinical hold since September 2021. In this part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.Question: Is there a standardized immunomodulation regimen being considered for gene therapy?Julie A. Parsons, MDAs I mentioned, right now, I think there are a number of different concepts that are being utilized. We don't really have a recommended standard regimen at this point. There are a number of different trials that are ongoing looking at trying to answer this question. In some of the clinical trials, there is an immune modulating regimen that is being put in place but being looked at. There isn't anything that we have as a standard at this moment for all gene transfer therapies, but I'm hopeful that we will come up with something that really makes sense in each patient population as we go forward with specific gene transfer therapies.Question: What are the long-term implications, safety and efficacy of a one-time gene therapy in pediatric patients with neuromuscular diseases?Alan Beggs, PhDOne question is the efficacy. For example, Donovan Decker's story, he had an experimental treatment of one muscle. It was a phase one safety trial, and he knew that nothing was going to come of it in terms of direct benefit to him. As a result, though, 25, 30 years later, he still has a tighter against AAV vectors. He's not a candidate for gene therapy under current protocols, although there's a lot of work going on to redosing. But for now, it's a one-time treatment. What you get is what you get, and there's not a chance to go back and do it again.The other question is durability. We really don't know about the long-term durability for these treatments. I should say that, for example, in the studies that we did, David Mack, who's here in the audience, managed a dog colony for a dog model of excellent tubular myopathy. Those animals lived 10 years in a... We never used the C-word, but they were cured. They were healthy, happy, normal dogs who would have had to be put down at 6 months of age otherwise. And then, as we heard, I'll let you talk about the concern for unanticipated SAEs as time goes on, but I think there's other aspects we need to think about.Julie A. Parsons, MDYeah. I think that this is really the key question that all of us are going to need to help answer over the next several years. Efficacy, we're looking at outcomes, and outcomes come in a variety of flavors. I think we do a decent job with motor outcomes. We don't do a decent job with some other outcomes. I think we need to look more broadly in terms of what we mean in terms of beneficial outcomes and really take some of those cues from the patients themselves about if these are efficacious treatments, because, again, the risk is high as we deliver these agents, and we need to know that it's worth it to the patients and families.In terms of safety, we're working on it. There are all sorts of things that are coming forward as issues with these patients. I think that collectively as a community, that our responsibility is to follow patients for the long term. There are lots of registries and outcome studies. We're not very good as a community about reporting adverse events to central groups. We're not great about broadcasting that to each other in real-time. I think those are things that we really need to work on as a community in terms of helping with the safety issues so that we all have a communal better understanding of what some of those issues are.

Today we are featuring two articles that relate to moving genetics into mainstream healthcare. In our first segment, we discuss polygenic risk scores and the transition from research to clinical use. Our second segment focuses on hypermobility Ehlers Danlos Syndrome and the triaging of clinical referrals.    Segment 1: Readiness and leadership for the implementation of polygenic risk scores: Genetic healthcare providers' perspectives in the hereditary cancer context   Dr Rebecca Purvis is a post-doctoral researcher, genetic counsellor, and university lecturer and coordinator at The Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, Australia. Dr Purvis focuses on health services delivery, using implementation science to design and evaluate interventions in clinical genomics, risk assessment, and cancer prevention.   In this segment we discuss: - Why leadership and organizational readiness are critical to successful clinical implementation of polygenic risk scores (PRS). - How genetic counselors' communication skills position them as key leaders as PRS moves from research into practice. - Readiness factors healthcare systems should assess, including culture, resources, and implementation infrastructure. - Equity, standardization, and implementation science as essential tools for responsible and sustainable PRS adoption. Segment 2: A qualitative investigation of Ehlers-Danlos syndrome genetics triage   Kaycee Carbone is  a genetic counselor at Boston Children's Hospital in the Division of Genetics and Genomics as well as the Vascular Anomalies Center. Her clinical interests include connective tissue disorders, overgrowth conditions, and somatic and germline vascular anomaly conditions. She completed my M.S. in Genetic Counseling at the MGH Institute of Health Professions in 2023. The work she discusses here, "A qualitative investigation of Ehlers-Danlos syndrome genetics triage," was completed as part of a requirement for this graduate program.    In this segment we discuss: - Why genetics clinics vary widely in how they triage referrals for hypermobile Ehlers-Danlos syndrome (hEDS). - How rising awareness of hEDS has increased referral volume without clear guidelines for diagnosis and care. - The ethical and emotional challenges genetic counselors face when declining hEDS referrals. - The need for national guidelines and clearer care pathways to improve access and coordination for EDS patients. Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

In this episode of the Authors On Mission Podcast, host Danielle Hutchinson sits down with T.L. McCoy to discuss her inspiring publishing journey and her award-winning book Delilah versus the Ghastly Grimm. Written for her grandchild who has Dravet syndrome, the book shines a light on the fact that only 3.4% of children's books feature disabled protagonists—and McCoy is determined to change that.She shares her mission to create inclusive stories, the challenges of self-publishing, and the marketing strategies that helped her book win 3 awards, hit #1 on Amazon's Children's Epilepsy Health list, and even be offered to patients at Boston Children's Hospital.Aspiring authors will gain valuable tips from McCoy's journey:

Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcomaOsteosarcoma Webinar Series: Katie Janeway, MD and Suzanne Forrest, MD join us on OsteoBites to discuss results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.Dr. Janeway received her MD and MMSc from Harvard Medical School. She completed her pediatrics residency and her Pediatric Hematology-Oncology fellowship at Boston Children's Hospital and Dana-Farber Cancer Institute. She is an Associate Professor of Pediatrics, a Senior Physician who cares for young people with sarcoma, and Director of Clinical Genomics. Dr. Janeway's research is focused on precision oncology and bone sarcomas. She leads clinical trials both as an independent investigator and as the Chair of the Children's Oncology Group (COG) Bone Tumor Committee. The Janeway Laboratory leads several studies, which have enrolled and sequenced more than 2,500 patients with childhood cancers. They are using this data to deepen the understanding of clinical and genomic factors explaining prognosis and treatment response, and resistance, with a focus on sarcomas. In collaboration with Count Me In, the group is innovating patient partnerships in sarcoma research.Dr. Forrest completed her medical school training at Yale University, followed by pediatrics training in the Boston Combined Residency Program. She then pursued a pediatric oncology fellowship at Dana-Farber Cancer Institute / Boston Children's Hospital. Currently, she serves as an Assistant Professor of Pediatrics at Harvard Medical School and an Attending Physician in the Department of Hematology/Oncology at Dana-Farber / Boston Children's Cancer and Blood Disorders Center. Her research focuses on developing novel clinical trials that utilize cancer genomics to guide treatment strategies for pediatric solid tumors.After a short presentation on this research, they will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

Send us a textThree third-year fellows present diverse research at Hot Topics. Dr. Tanima from Boston Children's demonstrates lung ultrasound's potential to predict respiratory support duration in 30+ week infants, with first six-hour exams showing strongest correlation—suggesting possible replacement for admission chest x-rays. Dr. Juhi from University of Illinois in Chicago applies large language models to extract IVH prognostic variables from AI literature, identifying critical gaps including absence of resolution prediction studies. Dr. Hailey conducts qualitative research on physician experiences with NICU mortality/morbidity, identifying three impactful loss categories: outcome-expectation mismatches, meaningful relationships, and weight of responsibilities. Their work exemplifies emerging neonatologist interests in point-of-care ultrasound, artificial intelligence applications, and clinician wellbeing. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry.UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Sharc Creative and Westchester Talk Radio proudly celebrated the 10th annual Stuff The Truck on Saturday and Sunday, December 6th and 7th, 2025, hosted at DeCicco & Sons locations in Sleepy Hollow and Armonk—where Quality First is lived every day. This community tradition once again rallied support for Feeding Westchester, helping bring fresh, nutritious meals to children, seniors, and families at a time when rising costs are making everyday essentials harder to afford. Thanks to generous holiday giving and the backing of sponsors including Norcom, Inspiria, 107.1 The Peak, 100.7 WHUD, Robison, PCSB Bank, Shleppers Moving & Storage, Purple Frog Graphics, and Boston Children's Health Physicians, Stuff The Truck continued its mission to ensure no neighbor goes hungry. UPDATE: As of 12/9/2025, our food collection equates to over 10,000 meals!

Mac Cerullo of the Boston Herald returns to talk to Ed and Owen about the state of the Boston Red Sox, the whispers and rumors making their way around winter meetings, training for the Boston Marathon, and much more.Mac is running the Boston Marathon in support of the hospital's Miles for Miracles program. Every dollar raised will go towards supporting Boston Children's Every Child Fund, which provides care and services for families throughout the hospital that aren't covered by insurance. You can donate in the link below. MFM - Boston Marathon 2026: Mr. Mac Anthony Cerullo - Boston Children's Hospital

Enid Martinez, MD is a Senior Associate in Critical Care at Boston Children's Hospital, and an Assistant Professor of Anaesthesia at Harvard Medical School. She is the Director of the Pediatric Critical Care Nutrition Program in the Division of Critical Care Medicine and Principal Investigator for a clinical-translational research program on gastrointestinal function and nutrition in pediatric critical illness.Learning Objectives:By the end of this podcast, listeners should be able to:Recognize the impact of nutritional status on outcomes of critically-ill children.Describe the key aspects of the metabolic stress response in critical illness.Discuss a clinical approach to accurately estimating and prescribing nutrition in critically-ill children.Reflect on an expert's approach to managing aspects of nutrition in critically-ill children where there may not be high-quality evidence. Selected references:Mehta et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):706-742. doi: 10.1177/0148607117711387. Epub 2017 Jun 2. PMID: 28686844. Fivez et al. Early versus Late Parenteral Nutrition in Critically Ill Children. N Engl J Med. 2016 Mar 24;374(12):1111-22. doi: 10.1056/NEJMoa1514762. Epub 2016 Mar 15. PMID: 26975590.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. You can also check out our website at http://www.pedscrit.com. Thank you for listening to this episode of PedsCrit!

In this Complex Care Journal Club podcast episode, Dr. Jody Lin discusses a qualitative study of shared decision-making for neuromuscular scoliosis surgery in children with medical complexity. She describes a broad range of family values and preferences that may guide decision-making, implications for clinical practice, and next steps from this work.‌ SPEAKER Jody Lin, MD, MS Pediatric Hospitalist Assistant Professor of Pediatrics Division of Inpatient Medicine University of Utah HOST Kathleen Huth, MD, MMSc Pediatrician, Complex Care Service, Division of General Pediatrics Boston Children's Hospital Assistant Professor of Pediatrics Harvard Medical School DATE Initial publication date: December 8, 2025. JOURNAL CLUB ARTICLE Lin JL, Devereaux T, Simon TD, Kaphingst KA, Zhu A, Narayanan U, Berry ABL, Eppich KG, Stoddard G, Smith JT, Andras L, Heflin J, Keenan HT, Asch SM, Fagerlin A. Caregiver Values and Preferences Related to Surgical Decision-Making for Children with Medical Complexity. J Pediatr. 2025 Jan;276:114366. doi: 10.1016/j.jpeds.2024.114366. Epub 2024 Oct 19. PMID: 39428089; PMCID: PMC11645212. OTHER ARTICLES REFERENCED Courageous Parents Network. Scoliosis and spine / spinal surgery: facts and decision-making. https://courageousparentsnetwork.org/guides/decision-making-around-spinal-fusion-surgery/. Accessed November 14, 2025. Lin JL, Clark CL, Halpern-Felsher B, Bennett PN, Assis-Hassid S, Amir O, Nunez YC, Cleary NM, Gehrmann S, Grosz BJ, Sanders LM. Parent Perspectives in Shared Decision-Making for Children With Medical Complexity. Acad Pediatr. 2020 Nov-Dec;20(8):1101-1108. doi: 10.1016/j.acap.2020.06.008. Epub 2020 Jun 12. PMID: 32540424; PMCID: PMC7655593. Lin JL, Cohen E, Sanders LM. Shared Decision Making among Children with Medical Complexity: Results from a Population-Based Survey. J Pediatr. 2018 Jan;192:216-222. doi: 10.1016/j.jpeds.2017.09.001. Epub 2017 Nov 6. PMID: 29102046; PMCID: PMC5732902. Lin JL, Tawfik DS, Gupta R, Imrie M, Bendavid E, Owens DK. Health and Economic Outcomes of Posterior Spinal Fusion for Children With Neuromuscular Scoliosis. Hosp Pediatr. 2020 Mar;10(3):257-265. doi: 10.1542/hpeds.2019-0153. PMID: 32079619; PMCID: PMC7041549.‌ TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/xcz7qm4n2b9rn636rrnq/Jody_Lin_Final_transcript_12-4-25.pdf. Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6. Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Lin JL, Huth K. Exploring What Matters: What Families Value in Complex Surgical Decision-Making. 12/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/exploring-what-matters-what-families-value-in-complex-surgical-decision-making.

Sonal N. Shah, MD, MPH, Division of Emergency Medicine, Boston Children's Hospital, Harvard Medical School, discusses the Rational Clinical Examination article "Has This Child Experienced Physical Abuse?" with JAMA Associate Editor David L. Simel, MD, MHS. Related Content: Has This Child Experienced Physical Abuse?

Enid Martinez, MD is a Senior Associate in Critical Care at Boston Children's Hospital, and an Assistant Professor of Anaesthesia at Harvard Medical School. She is the Director of the Pediatric Critical Care Nutrition Program in the Division of Critical Care Medicine and Principal Investigator for a clinical-translational research program on gastrointestinal function and nutrition in pediatric critical illness. Learning Objectives:By the end of this podcast, listeners should be able to:Recognize the impact of nutritional status on outcomes of critically-ill children.Describe the key aspects of the metabolic stress response in critical illness.Discuss a clinical approach to accurately estimating and prescribing nutrition in critically-ill children.Reflect on an expert's approach to managing aspects of nutrition in critically-ill children where there may not be high-quality evidence. Selected references:Mehta et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):706-742. doi: 10.1177/0148607117711387. Epub 2017 Jun 2. PMID: 28686844. Fivez et al. Early versus Late Parenteral Nutrition in Critically Ill Children. N Engl J Med. 2016 Mar 24;374(12):1111-22. doi: 10.1056/NEJMoa1514762. Epub 2016 Mar 15. PMID: 26975590.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

This week we go back in time to 2020 to delve into the topic of fellow wellness and review a work from the Boston Children's group on fellow fears and stressors when beginning their training. Are there patterns amongst the fellow concerns that can be identified and used to inform interventions to help allay these fears and reduce the stress? We speak with Dr. David Brown, Associate Professor of Pediatrics, Harvard Medical School and also Dr. Tony Pastor who was then the ACHD Fellow at Boston Children's Hospital/Brigham and Women's Hospital about their thoughts on fellow fears and stressors as well as fellow (and doctor) wellness. doi: 10.1007/s00246-019-02276-z.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children's Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:05 – Origins of the study, need to pursue more standardized care in IESS 4:40 – Reasons behind treatment variability after first and second-line options 8:00 – What research is needed to guide sequencing and standardize care 12:05 – Neurology News Minute 14:30 – What makes IESS studies difficult and how infrastructure can improve 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Dystrophinopathies are heritable muscle disorders caused by pathogenic variants in the DMD gene, leading to progressive muscle breakdown, proximal weakness, cardiomyopathy, and respiratory failure. Diagnosis and management are evolving areas of neuromuscular neurology. In this episode, Kait Nevel, MD, speaks with Divya Jayaraman, MD, PhD, an author of the article "Dystrophinopathies" in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Jayaraman is an assistant professor of neurology and pediatrics in the division of child neurology at the Columbia University Irving Medical Center in New York, New York. Additional Resources Read the article: Dystrophinopathies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today I'm interviewing Dr Divya Jayaraman about her article on dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Divya, welcome to the podcast, and please introduce yourself to the audience. Dr Jayaraman: Thank you so much, Dr Nevel. My name is Divya, and I am an assistant professor of Neurology and Pediatrics at Columbia University Irving Medical Center, and also an attending physician in the Pediatric Neuromuscular program there. In that capacity, I see patients with pediatric neuromuscular disorders and also some general pediatric neurology patients and also do research, primarily clinical research and clinical trials on pediatric neuromuscular disorders. Dr Nevel: Wonderful. Thank you for sharing that background with us. To set us on the same page for our discussion, before we get into some more details of the article, perhaps, could you start with some definitions? What comprises the dystrophinopathies? What are some of the core features? Dr Jayaraman: So, the dystrophinopathies, I like that term because it is a smaller subset from the muscular dystrophies. The dystrophinopathies are a spectrum of clinical phenotypes that are all associated with mutations in the DMD gene on chromosome X. So, that includes DMD---or, Duchenne muscular dystrophy---, Becker muscular dystrophy, intermediate muscular dystrophy (which falls in between the two), dilated cardiomyopathy, asymptomatic hyperCKemia, and manifesting female carriers. In terms of the core features of these conditions, so, there's some variability, weakness being prominent in Duchenne and also Becker. The asymptomatic hyperCKemia, on the other hand, may have minimal symptoms and might be found incidentally by just having a high CK on their labs. They all will have some degree of elevated CK. The dilated cardiomyopathy patients, and also the Becker patients to a lesser degree, will have cardiac involvement out of proportion to skeletal muscle involvement, and then the manifesting carriers likewise can have elevated CK and prominent cardiac involvement as well as some milder weakness. Dr Nevel: Now that we have some definitions, for the practicing neurologists out there, what do you think is the most important takeaway from your article about the dystrophinopathies? Dr Jayaraman: I like this question because it suggests that there's something that, really, any neurologist could do to help us pick up these patients sooner. And the big takeaway I want everyone to get from this is to check the CK, or creatine kinase, level. It's a simple, cheap, easy test that anyone can order, and it really helps us a lot in terms of setting the patient on the diagnostic odyssey. And in terms of whom you should be thinking about checking a CK in, obviously patients who present with some of the classic clinical features of Duchenne muscular dystrophy. This would include young boys who have toe walking, as they're presenting, sign; or motor delayed, delayed walking. They may have calf hypertrophy, which is what we say nowadays. You might have seen calf pseudohypertrophy in your neurology textbooks, but we just say calf hypertrophy now. Or patients can often have a Gowers sign or Gowers maneuver, which is named after a person called Gowers who described this phenomenon where the child will basically turn over and use their hands on the floor to stand up, usually with a wide-based gait, and then they'll sort of march their hands up their legs. That's the sort of classic Gowers maneuver. There are modified versions of that as well. So, if anyone presents with this classic presentation, for sure the best first step is to check a CK. But I would also think about checking a CK for some atypical cases. For example, any boy with any kind of motor or speech delay for whom you might not necessarily be thinking about a muscle disorder, it's always good practice to check a CK. Even a boy with autism for whom you may not get a good clinical exam. This patient might present to a general pediatric neurology clinic. I always check a CK in those patients, and you'll pick up a lot of cases that way. For the adult folks in particular, the adult neurologist, a female patient could show up in your clinic with asymptomatic hyperCKemia. And I think it's an important differential to think about for them because this could have implications not just for their own cardiac risks, but also for their family planning. Dr Nevel: So, tell us a little bit more about the timing of diagnosis. Biggest takeaway: check a CK if this is anywhere on your radar, even if somewhat of an atypical case. Why is it so important to get kiddos started on that diagnostic odyssey, as you called it, early? Dr Jayaraman: This is especially important for kids because if they especially get a Duchenne muscular dystrophy diagnosis, you might be making them eligible for treatments that we've had for some time, and also treatments that were not available earlier that hinge on making that diagnosis. So, for example, people may be skeptical about steroids, but there's population data to suggest that initiation and implementation of steroids could delay the onset of loss of ambulation as much as three years. So, you don't want to deprive patients of the chance to get that. And then all the newer emerging therapies---which we'll be talking about later, I'm sure---require a Duchenne muscular dystrophy diagnosis. So, that's why it's so important to check a CK, have this on your radar, and then get them to a good specialist. Dr Nevel: I know that you alluded already, or shared a few of the kind of exam paroles or findings among patients with dystrophinopathy. But could you share with us a little bit more how you approach these patients in the clinic who are presenting with muscle weakness, perhaps? And how do you approach this or think about this in terms of ways to potentially differentiate between a dystrophinopathy versus another cause of motor weakness or delay? Dr Jayaraman: It's helpful to think through the neuraxis and what kinds of disorders can present along that neuraxis. A major differential that I'm always thinking about when I'm seeing a child with proximal weakness is spinal muscular atrophy, which is a genetic anterior horn cell disorder that can also present in this age group. And some of the key differences there would be things like reflexes. So, you should have dropped reflexes in spinal muscular atrophy. In DMD, surprisingly, they might have preserved Achilles reflexes even if their patellar reflexes are lost. It may only be much later that they go on to lose their Achilles reflex. So, if you can get an Achilles reflex, that's quite reassuring, and if you cannot, then you need to be thinking about spinal muscular atrophy. They can both have low muscle tone and can present quite similarly, including with proximal weakness, and can even have neck flexion weakness. So, this is an important distinction to make. The reason for that is, obviously there are treatments for both conditions, but for spinal muscular atrophy, timing is very, very important. Time is motor neurons, so the sooner you make that diagnosis the better. Other considerations would be the congenital muscular dystrophies. So, for those that they tend to present a lot younger, like in infancy or very early on, and they can have much, much higher CKS in that age range than a comparable Duchenne or Becker muscular dystrophy patient. They can also have other involvement of the central nervous system that you wouldn't see in the dystrophinopathies, for example. My mnemonic for the congenital muscular dystrophies is muscle-eye-brain disease, which is one of the subtypes. So, you think about muscle involvement, eye involvement, and brain involvement. So, they need an ophthalmology valve. They can have brain malformations, which you typically don't see in the dystrophinopathies. I think those are some of the major considerations that I have. Obviously, it's always good to think about the rest of the neuraxis as well. Like, could this be a central nervous system process? Do they have upper motor neuron signs? But that's just using all of your exam tools as a neurologist. Dr Nevel: Yeah, absolutely. So, let's say you have a patient in clinic and you suspect they may have a dystrophinopathy. What is your next diagnostic step after your exam? Maybe you have an elevated CK and you've met with the patient. What comes next? Dr Jayaraman: Great question. So, after the CK, my next step is to go to genetics. And this is a bit of a change in practice over time. In the past we would go from the CK to the muscle biopsy before genetic testing was standard. And I think now, especially in kids, we want to try and spare them invasive procedures where possible. So, genetic testing would be the next step. There are a few no-charge, sponsored testing programs for the dystrophinopathies and also for some of the differential diagnosis that I mentioned. And I think we'll be including links to websites for all of these in the final version of the published article. So, those are a good starting point for a genetic workup. It's really important to know that, you know, deletions and duplications are a very common type of mutation in the DMD gene. And so, if you just do a very broad testing, like whole exome, you might miss some of those duplications and deletions. And it's important to include both checking for duplications and deletions, and also making sure that the DMD gene is sequenced. So always look at whatever genetic test you're ordering and making sure that it's actually going to do what you want it to do. After genetics, I think that the sort of natural question is, what if things are not clear after the genetics for some reason? We still use biopsy in this day and age, but we save it for those cases where it's not entirely clear or maybe the phenotype is a little bit discordant from the genotype. So, for mutations that disrupt the reading frame, those tend to cause Duchenne muscular dystrophy, whereas mutations that preserve the reading frame tend to cause Becker muscular dystrophy. There are some important exceptions to this, which is where muscle biopsy can be especially helpful in sorting it out. So, for example, there are some early mutations early in the DMD gene where, basically, they find an alternate start codon or an initiation codon to continue with transcription and translation. So, you end up forming a largely functional, somewhat truncated protein that gives you more of a milder Becker phenotype. On the other hand, you can have some non-frameshift or inframe mutations that preserve the reading frame, but because they disrupt a very key domain in the protein that's really crucial for its function, you can actually end up with a much more severe Duchennelike phenotype. So, for these sorts of cases, you might know a priori you're dealing with them, but might just be a child who is who you think has DMD has a mutation that's showed up on testing. There isn't enough in the literature to point you one way or another, but they look maybe a little milder than you would expect. That would be a good kid to do a biopsy in because there are treatment decisions that hinge on this. There are treatments that are only for Duchenne that someone with a milder phenotype would not be eligible for. Dr Nevel: So, that kind of stepwise approach, but maybe not all kids need a muscle biopsy is what I'm hearing from you. If it's a mutation that's been well-described in the literature to be fitting with Duchenne, for example. Dr Jayaraman: Absolutely. Dr Nevel: So, after you confirm the diagnosis through genetic testing---and let's say, you know, whether or not you do a muscle biopsy or not, after you know the diagnosis is a dystrophinopathy---how do you counsel the families and your patients? What are the most important points to relay to families, especially in that initial phase where the diagnosis is being made? Dr Jayaraman: This is a lot of what we do in pediatric neurology in general, right? So, I actually picked up this approach from the pediatric hematology oncology specialists at Boston Children's. They had this concept of a day-zero conversation, which is the day that you disclose the life-changing diagnosis or potentially, at some point, terminal diagnosis to a family. And some of the key components of that are a not beating around the bush, telling them what the diagnosis is, and then letting them have whatever emotional response they're going to have in the moment. And you may not get much further than that, but honestly, you want them to take away, this is what my child has. I did not do anything to cause this, nor could I have done anything to prevent this. Because often for these genetic conditions, there's a lot of guilt, a lot of parental guilt. So, you want to try and assuage that as much as possible. And then to know that they're not going to be alone on this journey; that, you know, they don't have to have it all figured out right then, but we can always come back and answer any questions they have. There's going to be a whole team of specialists. We're going to help the family and the kid manage this condition. Those are sort of my big takeaways that I want them to get. Dr Nevel: Right. And that segues into my next question, which is, who is part of that team? I know that these teams that help take care of people with dystrophinopathies and other muscle disorders can be very large teams that span multiple specialists. Can you talk a little bit more about that for this group of patients? Dr Jayaraman: Of course. So, the neuromuscular neurologist, really, our role is in coordinating the diagnosis, the initiation of any disease-specific treatments, and coordinating care with a whole group of specialists. So, we're sort of at the center of that, but everyone else is equally important. So, the other specialists include physical therapists; occupational therapists; rehab doctors or physiatrists; orthotists who help with all of the many braces and other devices that they might need, wheelchairs; pulmonology, of course, for managing the respiratory manifestations of this. It becomes increasingly important over time, and they are involved early on to help monitor for impending respiratory problems. Cardiac manifestations, this is huge and something that you should be thinking about even for your female carriers, the mother of the patient you're seeing in the clinic, or your patient who comes to adult clinic with asymptomatic hyperCKemia. if you end up making a diagnosis of DMD carrier for those patients, or if you make a Becker diagnosis, the cardiac surveillance is even more important because the cardiac involvement can be out of proportion to the skeletal muscle weakness. And of course, extremely important for the Duchenne patients as well. Endocrinologists are hugely important because in the course of treating patients with steroids, we end up giving them a lot of iatrogenic endocrinologic complications. Like they might have delayed puberty, they might have loss of growth, of height; and of course metabolic syndrome. So, endocrinology is hugely important. They're also important in managing things like fracture prevention, osteoporosis, prescribing bisphosphonates if necessary. Nutrition and GI are also important, not just later on when they might need assistance to take in nutrition, whether that's through tube feeds, but also earlier on when we're trying to manage the weight. Orthopedics, of course, for the various orthopedic complications that patients develop. And then finally, a word must be said for social work and behavioral and mental health specialists, because a lot of this patient population has a lot of mental health challenges as well. Dr Nevel: After you give the diagnosis, you've counseled the patient and families and you've had those kind of initial phase discussions, the day-zero discussion, when you start getting into discussions or thoughts about management, disease-specific medication. But what are the main categories of the treatment options, and maybe how do you kind of approach deciding between treatment options for your patients? Dr Jayaraman: So, there are two broad categories that I like to think about. So, one is the oral corticosteroids and oral histone deacetylase, or HDAC inhibitors, which share the common characteristic that they are non-mutation specific. And within corticosteroids, patients now have a choice between just Prednisone or Prednisolone, or Deflazacort or Vermilion. The oral HDAC inhibitors are newly FDA-approved as a nonsteroidal therapy in addition to corticosteroids in DMD patients above six years of age. I would say we're in the early phase of adoption of this in clinical practice. And then the other big category of treatment options would be the genetic therapies as a broad bucket, and this would include gene therapy or gene replacement therapy, of which the most famous is the microdystrophin gene therapy that was FDA-approved first on an accelerated approval basis for ages four to eight, and then a full approval in that age group as well as an accelerated approval for all comers, essentially, with DMD. This is obviously controversial. Different centers approach this a bit differently. I think our practice at our site has been to focus on the ambulatory population, just thinking about risk versus benefit, because the risks are not insignificant. So really this is something that should be done by experienced sites that have the bandwidth and the wherewithal to counsel patients through all of this and to manage complications as they arise with regular monitoring. And then another class that falls within this broader category would be the Exon-skipping therapies. So as the name suggests, they are oligonucleotides that cause an Exon to be skipped. The idea is, if there is a mutation in a particular Exon that causes a frame shift, and there's an adjacent Exon that you can force skipping of, then the resulting protein, when you splice the two ends together, will actually allow restoration of the reading frame. I think the picture I want to paint is that there's a wide range of options that we present to families, not all of which everyone will be eligible for. And they all have different risk profiles. And I really think the choice of a particular therapy has to be a risk-benefit decision and a shared decision-making process between the physician and the family. Dr Nevel: What is going on in research in this area? And what do you think will be the next big breakthrough? I know before we started the recording you had mentioned that there's a lot of things going on that are exciting. And so, I'm looking forward to hearing more. Dr Jayaraman: Of course. So, I'll be as quick as I can with this. But I mentioned that next-generation Exon skipping therapies, I think the hope is that they will be better at delivering the Exon skipping to the target tissue and cells and that they might be more efficacious. I'm also excited about next-generation gene therapies that might target muscle more specifically and hopefully reduce the off-target effects, or combination use of gene therapies with other immunosuppressive regimens to improve the safety profile and maybe someday allow redosing, which we cannot do currently. Or potentially targeting the satellite cells, which are the muscle stem cells, again, to improve the long term durability of these genetic therapies. Dr Nevel: That's great, thank you for sharing. Thank you so much for talking to me today about your article. I really enjoyed learning more about the dystrophinopathies. Today I've been interviewing Dr Divya Jayaraman about her article on the dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out the Continuum Audio episodes from this and other issues. Also, please read the Continuum articles for more details than what we were able to get to today during our discussion. Thank you, as always, so much to the listeners for joining us today, and thank you, Divya, for sharing all of your knowledge with us today. Dr Jayaraman: Thank you so much for having me on the podcast. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In this World Shared Practice Forum Podcast, Dr. Vinay Nadkarni discusses emergent tracheal intubation in pediatric critical care. Drawing from the NEAR4KIDS registry and comparing with recent adult-focused evidence, Dr. Nadkarni discusses the challenges of airway management in children, emphasizing the importance of patient-specific physiology. He highlights how patient positioning and equipment choices can improve intubation outcomes. Additionally, the episode explores the benefits of video laryngoscopy and apneic oxygenation. This content is pertinent for healthcare professionals seeking to enhance their understanding of pediatric airway management, offering practical insights supported by recent research. LEARNING OBJECTIVES - Compare pediatric and adult emergency tracheal intubation evidence and practices - Explore the role of the NEAR4KIDS registry in improving pediatric intubation practices - Identify effective strategies to enhance first-attempt success in tracheal intubations - Assess the impact of patient positioning and equipment choices on intubation outcomes - Evaluate the benefits of video laryngoscopy and apneic oxygenation in pediatric settings AUTHORS Vinay Nadkarni, MD, MS Professor, Anesthesiology Critical Care and Pediatrics University of Pennsylvania Perelman School of Medicine Jeffrey Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: November 25, 2025. ARTICLES REFERENCED - DeMasi SC, Casey JD, Semler MW. Evidence-based Emergency Tracheal Intubation. Am J Respir Crit Care Med. 2025;211(7):1156-1164. doi:10.1164/rccm.202411-2165CI - Garcia-Marcinkiewicz AG, Kovatsis PG, Hunyady AI, et al. First-attempt success rate of video laryngoscopy in small infants (VISI): a multicentre, randomised controlled trial. Lancet. 2020;396(10266):1905-1913. doi:10.1016/S0140-6736(20)32532-0 - Hagberg CA, Artime CA, Aziz MF, eds. Hagberg and Benumof's Airway Management. 5th ed. Philadelphia, PA: Elsevier; 2023. - Khanam D, Schoenfeld E, Ginsberg-Peltz J, et al. First-Pass Success of Intubations Using Video Versus Direct Laryngoscopy in Children With Limited Neck Mobility. Pediatr Emerg Care. 2024;40(6):454-458. doi:10.1097/PEC.0000000000003058 - Waheed S, Kapadia NN, Jawed DR, Raheem A, Khan MF. Randomized controlled trial to assess the effectiveness of apnoeic oxygenation in adults using a low-flow or high-flow nasal cannula with head side elevation during endotracheal intubation in the emergency department. BMC Res Notes. 2025 Jul 1;18(1):264. doi: 10.1186/s13104-025-07328-7. Erratum in: BMC Res Notes. 2025 Sep 8;18(1):384. doi: 10.1186/s13104-025-07412-y. PMID: 40598378; PMCID: PMC12219693. TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/mr2657n4ckgpz7g3tw37gbx/202511_WSP_Nadkarni_transcript Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Nadkarni V, Burns JP. Pediatric Intubation Practices: Insights from NEAR4KIDS. 11/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/pediatric-intubation-practices-insights-from-near4kids-by-v-nadkarni-openpediatrics.

Does cannabis use have any effect, good or bad, on Orthopaedic Surgery? It's a question we, as a Sports Medicine community, hear increasingly frequently from our patients but so far don't have great data to provide sound advice. We welcome Dr. Grant Hogue who has studied this extensively across several disciplines of Orthopaedic Surgery. He presents his work with his colleagues at Boston Children's Hospital looking specifically at adverse effects of marijuana use on ACL reconstruction recovery.

In this Nursing World Shared Practice Forum Podcast, Dr. Bernadette Melnyk, a globally renowned expert in evidence-based practice (EBP), discusses the critical importance of EBP in healthcare. This podcast covers the history of EBP, its impact on patient outcomes, and the return on investment for healthcare systems. Dr. Melnyk shares insights on building a culture that supports EBP, the role of EBP mentors, and the importance of clinician well-being. LEARNING OBJECTIVES - Identify strategies for creating and sustaining a culture that prioritizes EBP within healthcare organizations - Recognize the role of EBP mentors in facilitating the implementation of evidence-based changes - Explore the relationship between EBP, clinician well-being, and job satisfaction - Understand the organizational benefits of EBP initiatives as measured by return on investment (ROI) and value of investment (VOI) - Learn the difference between EBP and Implementation Science AUTHORS Bernadette Melnyk, PhD, APRN-CNP, EBP-C, FAANP, FNAP, FAAN CEO and Founder, COPE2Thrive, LLC President and Co-Founder, EBP Solutions, LLC Professor and Dean Emeriti Editor-in-Chief, Worldviews on Evidence-based Nursing Ethan Schuler, DNP, RN, CPNP-AC/PC, APN II Surgical Nurse Practitioner, Division of Critical Care Medicine Boston Children's Hospital DATE Initial publication date: November 18, 2025. ARTICLES REFERENCED 1) Melnyk BM, Strait LA, Beckett C, Hsieh AP, Messinger J, Masciola R. The state of mental health, burnout, mattering and perceived wellness culture in Doctorally prepared nursing faculty with implications for action. Worldviews Evid Based Nurs. 2023;20(2):142-152. doi:10.1111/wvn.12632 2) Melnyk BM, Hsieh AP, Tan A, et al. Associations Among Nurses' Mental/Physical Health, Lifestyle Behaviors, Shift Length, and Workplace Wellness Support During COVID-19: Important Implications for Health Care Systems. Nurs Adm Q. 2022;46(1):5-18. doi:10.1097/NAQ.0000000000000499 3) Melnyk BM, Davidson JE, Tucker S, et al. Burnout, Mental Health, and Workplace Characteristics: Contributors and Protective Factors Associated With Suicidal Ideation in High-Risk Nurses. Worldviews Evid Based Nurs. 2025;22(3):e70042. doi:10.1111/wvn.70042 4) Melnyk BM, Hsieh AP, Messinger J, Thomas B, Connor L, Gallagher-Ford L. Budgetary investment in evidence-based practice by chief nurses and stronger EBP cultures are associated with less turnover and better patient outcomes. Worldviews Evid Based Nurs. 2023;20(2):162-171. doi:10.1111/wvn.12645 TRANSCRIPT Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Melnyk BM, Schuler E, DeGrazia M. Transforming Healthcare with Evidence-Based Practice. 11/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/transforming-healthcare-with-evidence-based-practice-by-b-melnyk-openpediatrics.

Missed PCICS 2025? Join hosts Deanna Tzanetos MD (Norton Children's Hospital/U of Louisville), Kavipriya Komeswaran MD (U of Mississippi) and Maria Batsis MD (Lucile Packard Children's/Stanford University) as they interview two of the speakers from the PCICS 2025 session on the challenges of Shone's Complex- Michael DiMaria MD (Rocky Mountain Children's Hospital) and Jessica Barreto MD, MS (Boston Children's Hospital, Harvard University). Editor and Producer: Lillian Su, MD (Children's National Hospital).

S7 E3: Autism and Executive Functions w/Dr. Susan FajaIn this episode, Gerald and Alexis are joined by Dr. Susan Faja - clinical psychologist from Boston Children's Hospital - to discuss executive functions among individuals on the Autism spectrum. In this valuable discussion, you will learn how executive function challenges present in ASD, the individual differences among the ASD population, how to support executive function for those with ASD, and recent research findings about Autism.Dr. Susan Faja, who is a psychologist at Boston Children's Hospital specializing in the research of individuals with Autism, particularly children. The Faja Lab led by Dr. Faja seeks to understand changes in brain systems of executive control, social cognition and social perception resulting from targeted interventions that use electrophysiological as well as behavioral measurement tools. She leads the Faja Lab, where her approach allows for the exploration of the developmental processes that contribute to behavioral symptoms, clarifies how interventions work, and provides a platform for rigorously testing novelinterventions. Additionally, Dr. Faja seeks to understand why and how individuals with Autism can present so differently in their development, as a way to better understand causes and inform individualized treatments.

In this special Complex Care Journal Club podcast episode, host Dr. Kilby Mann interviews presenters of posters and oral abstracts relevant to the care of children with medical complexity at the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) 79th Annual Meeting, October 15-18, 2025, in New Orleans, Louisiana. Speakers describe their study findings and implications for practice. Dr. Francisco Valencia also discusses the role of the Complex Care Committee and the profound impact of mentorship in the field of complex care. SPEAKERS Laura Brunton, PT, PhD, Associate Professor, School of Physical Therapy, Western University, London, Ontario, Canada Caitlin Cassidy, MD, Associate Professor, Department of Physical Medicine and the Department of Rehabilitation and Pediatrics, Western University, London, Ontario, Canada Susan Gibb, MBBS, FRACP, Medical Lead, Complex Care Hub, Royal Children's Hospital, Melbourne, Australia Francisco Valencia, MD, Pediatric Orthopedic Surgeon, Children's Clinics For Rehabilitative Services, Tucson, Arizona Simran Prakash, BA, Medical Student, University of Miami Miller School of Medicine Karen Pratt, BA, MSc, PhD Candidate, Western University School of Health Sciences, London, Ontario, Canada Claire Wallace, PhD, Pediatric Psychologist, Ranken Jordan Pediatric Bridge Hospital, Maryland Heights, Missouri Esther Yap, BPharm, MD, Physician, Royal Children's Hospital, Melbourne, Australia HOST Kilby Mann, MD, Assistant Professor, Pediatric Rehabilitation Medicine, Children's Hospital Colorado DATE Initial publication date: November 11, 2025. RESOURCES REFERENCED - American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) 29th Annual Meeting, October 15-18, 2025, New Orleans, LA. https://www.aacpdm.org/events/2025/program - American Academy for Cerebral Palsy and Developmental Medicine (AACPDM), www.aacpdm.org/ - AACPDM Complex Care Committee (www.aacpdm.org/about-us/committees/complex-care) TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/bgmft56r8ksk85qxbthvzs/CCJCP_AACPDM_Transcript_11-4-25‌ Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6. Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Valencia F, Brunton L, Cassidy C, Gibb S, Prakash S, Pratt K, Wallace C, Yap E, Mann K. Practice-Changing Research in Complex Care at the AACPDM Annual Meeting 2025. 11/2025. OPENPediatrics. Online Podcast.‌ https://soundcloud.com/openpediatrics/practice-changing-research-in-complex-care-at-the-aacpdm-annual-meeting-2025.

Send us a textJoin Dr. Grant Hogue as he talks with his office mate, Dr. John Emans, the 2025 Lifetime Achievement Award Winner! This prestigious honor recognizes an SRS member for distinguished service to the Society as well as significant contributions to spinal deformity care. Listen to hear about what lead him to where he is today and his amazing career at Boston Children's Hospital. *The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.

Milk has long been sold as the key to strong bones, but research challenges that claim: many people don't tolerate dairy, calcium needs are lower than advertised, and higher milk intake doesn't necessarily prevent fractures. Politics and industry marketing helped set “three glasses a day,” even though healthy bones depend more on overall diet and lifestyle—things like vitamin D, movement, and avoiding soda, excess sugar, and stress that drive calcium loss. Dairy may be helpful for some diets, but it can also trigger bloating, acne, congestion, or digestive issues. The good news is that strong bones and good nutrition are still very doable without cow's milk—think leafy greens, sardines, almonds, chia, and sunshine for vitamin D. In this episode, I discuss, along with Dr. David Ludwig and Dr. Elizabeth Boham why bone health depends more on diet, lifestyle, and nutrient balance than on dairy. David S. Ludwig, MD, PhD, is an endocrinologist and researcher at Boston Children's Hospital, Professor of Pediatrics at Harvard Medical School, and Professor of Nutrition at the Harvard T.H. Chan School of Public Health. He co-directs the New Balance Foundation Obesity Prevention Center and founded the Optimal Weight for Life (OWL) program, one of the nation's largest clinics for children with obesity. For over 25 years, Dr. Ludwig has studied how diet composition affects metabolism, body weight, and chronic disease risk, focusing on low glycemic index, low-carbohydrate, and ketogenic diets. Called an “obesity warrior” by Time Magazine, he has championed policy changes to improve the food environment. A Principal Investigator on numerous NIH and philanthropic grants, Dr. Ludwig has published over 200 scientific articles and three books for the public, including the #1 New York Times bestseller Always, Hungry? Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:Why Most Everything We Were Told About Dairy Is Wrong Is It Okay To Eat Cheese And What Types Of Dairy Should You Avoid? Is Lactose Intolerance Causing Your Gut Issues?

The Triple Threat to the Rare Disease Ecosystem — A Conversation with Dr. Wendy ChungSometimes you come across someone whose work changes the way you think about an entire field. That's exactly what happened when I read about Dr. Wendy Chung in Rare Revolution Magazine.Dr. Chung is one of those rare people who stands at the intersection of science, medicine, ethics, and humanity. She's a clinical and molecular geneticist, the Chief of Pediatrics at Boston Children's Hospital, and the Mary Ellen Avery Professor at Harvard Medical School. She leads NIH-funded research into the genetics of conditions like pulmonary hypertension, autism, birth defects, and a wide range of rare diseases. She's advanced newborn screening for life-threatening disorders like spinal muscular atrophy and Duchenne muscular dystrophy — work that means the difference between life and death for many families. She's been recognized with the Rare Impact Award from NORD, is a member of the National Academy of Medicine, and is a leading voice on the ethics of genomics.But titles and accolades only tell part of her story. What stands out most is her deep commitment to the people behind the science, the families living day in and day out with conditions that most of the world has never heard of.When we spoke, Dr. Chung described what she calls the “triple threat” to the rare disease ecosystem:Misinformation in health that spreads faster than facts and erodes trust in science.Lack of access to healthcare, leaving too many without the treatments they need, when they need them.Insufficient investment in research, slowing the pace of discovery and delaying life-saving therapies.Each of these challenges is daunting on its own, but together they create a fragile and often hostile environment for progress in rare disease research and care.She pointed out that while most genetic conditions are rare individually, collectively they are surprisingly common — affecting millions worldwide. That's a staggering thought, especially considering how little public awareness and funding rare diseases often receive.We also talked about autism, a condition she has studied extensively. She emphasized that autism is a spectrum, with multiple causes, the majority of which are genetic. Understanding that complexity is crucial, not only for advancing science but also for helping families cope and make informed decisions.One of the threads running through our conversation was the urgent need for better communication in science. In an age where misinformation spreads in seconds, the ability to convey facts clearly and accessibly isn't just a nice skill — it's a necessity. Miscommunication or confusion doesn't just impact public opinion; it influences policy decisions, research funding, and the direction of healthcare itself.Dr. Chung stressed that advocacy matters at every level — from the conversations parents have with their children's doctors to the policies shaped in Washington. Community engagement isn't just a feel-good idea; it's one of the most effective ways to accelerate progress. Patients, families, scientists, and policymakers all have a role to play, and collaboration among them is where breakthroughs happen.In the end, our conversation left me with two truths. First, that rare disease progress depends on persistence from so many people. The researchers who refuse to give up, from families who continue to fight for answers, and from advocates who push for change. Second, that truth itself is a kind of medicine. The more accurately, compassionately, and consistently we can communicate about rare diseases, the better chance we have at building a healthcare ecosystem that works for everyone.Dr. Wendy Chung is leading that charge, not just in the lab, but in the public square. And in this fight, both matter equally. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

In this episode, Amber Borucki, MD from Stanford Medicine, joins Host Sudheer Potru, DO, FASA, FASAM, and Co-Host Zafeer Baber, MD, to discuss acetaminophen use during pregnancy and childhood. They focus on a significant Swedish study that dispels myths about acetaminophen's links to autism, reinforcing its safety and effectiveness. Dr. Borucki highlights its role in pain management for expectant mothers and children, while the hosts discuss alternatives to opioids, like acetaminophen and ibuprofen, and stress the importance of consulting healthcare providers for proper dosing and guidance.About the GuestDr. Amber Borucki is an anesthesiologist and pain medicine specialist focused on chronic pain management in children and young adults, particularly after surgery or due to chronic conditions. She earned her medical degree from Rush Medical College and completed her residency at the University of Chicago. Dr. Borucki also underwent fellowships in pediatric anesthesiology and adult/pediatric pain medicine at Boston Children's Hospital, Brigham Women's Hospital, and Beth Israel Deaconess Medical Center. After a year of private practice in Reno, Nevada, she spent five years at UCSF as a pediatric anesthesiologist and the Director of the Pediatric Anesthesia Service at UCSF Benioff Children's Hospital.   

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Listen to the podcast here

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Download the transcript here

This week, I'm joined by Dr. Felice Chan, a Chinese medicine doctor who bridges Eastern and Western approaches to healing after years studying allopathic medicine including shadowing an oncology neurosurgeon and working at Boston Children's Hospital. We dive into the fascinating contrasts between healthcare in Hong Kong and the U.S., the 5,000-year misunderstanding around acupuncture, and how our gut health connects to anxiety, depression, and even our skin. Dr. Chan shares practical, science-backed tips to reduce bloating, support digestion, curb sugar cravings, and shift your mindset around food—plus her honest takes on popular health trends like intermittent fasting and cold plunging. We also get into cosmetic acupuncture, what not to do on your period, how emotions manifest physically, and how to “eat your skincare” by nourishing your blood and creating a vibrant, resilient body from the inside out.This episode is brought to you by:Get 20% off your order at Bakedbymelissa.com/BLONDE.Go to ProLonLife.com/BLONDE for 15% off plus a $40 bonus gift when you subscribe to their 5-day program.Visit Hungryroot.com/blonde and use code blonde for 40% off your first box.Go to fromourplace.com/BLONDE and use code BLONDE for 10% off sitewide.Get $10 off your first month's subscription and enjoy free shipping when you visit Nutrafol.com and use promo code BLONDE.Go to Quince.com/blonde for 365-day returns, plus free shipping on your order.Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Juan Melero-Martin is an Associate Professor and the Endowed Chair in Cardiac Surgery at Boston Children's Hospital. His lab uses bioengineering principles to understand how vascular networks are formed and the mechanisms by which the vasculature modulates the engraftment and activity of various human stem cells.

In this World Shared Practice Forum podcast, Dr. Robinder Khemani, co-author of the PALICC-2 guidelines, discusses the real-world application of pediatric ARDS management strategies. Through a case-based conversation, Dr. Khemani shares nuanced insights on intubation timing, ventilator settings, neuromuscular blockade, and rescue therapies, including ECMO. He also introduces the REDvent trial, a novel approach to lung and diaphragm protective ventilation. This content is ideal for clinicians, respiratory therapists, and healthcare educators seeking to deepen their understanding of evidence-informed, physiology-driven care in pediatric acute respiratory distress syndrome. LEARNING OBJECTIVES - Analyze the clinical decision-making process for intubation in pediatric ARDS - Apply PEEP titration techniques to assess lung recruitability in patients with PARDS - Evaluate the role of neuromuscular blockade in maintaining lung protective ventilation - Identify appropriate advanced rescue therapies based on PARDS phenotypes - Explore the principles and outcomes of the REDvent trial in ventilator management AUTHORS Robinder "Roby" Khemani, MD, MsCI Professor of Pediatrics, Vice Chair of Research University of Southern California, Department of Anesthesiology and Critical Care Medicine Children's Hospital Los Angeles Jeffrey Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: October 28, 2025. ARTICLE REFERENCED Khemani RG, Bhalla A, Hotz JC, et al. Randomized Trial of Lung and Diaphragm Protective Ventilation in Children. NEJM Evid. 2025;4(6):EVIDoa2400360. doi:10.1056/EVIDoa2400360 TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/47wbxnvxtcpvv54p48gc2v/202510_WSP_Khemani_Transcript.pdf Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Khemani RG, Burns JP. Practical Strategies for Management of Patients with Pediatric ARDS. 10/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/practical-strategies-for-management-of-patients-with-pediatric-ards-by-r-khemani-openpediatrics.

This week we take a closer look at Retinopathy of Prematurity (ROP) -  from screening and staging to treatment and long-term outcomes. Join us as we shine some light on this sight-saving topic with insights from Dr. Nimesh Patel - Assistant Professor of Ophthalmology at Harvard Medical School and the director of Pediatric Vitreoretinal Surgery at Boston Children's Hospital. You won't believe your eyes at how much there is to see in the world of ROP care!

In this episode, Press Ganey CEO Pat Ryan talks with Dr. Kevin B. Churchwell, President and CEO of Boston Children's Hospital, about building a culture of safety and trust and how transparency, a shared safety language, and daily huddles turn good intentions into measurable outcomes.This episode is sponsored by Press Ganey.

In this special Complex Care Journal Club podcast episode, co-hosts Kilby Mann, Kristie Malik, and Kathleen Huth interview presenters of posters relevant to the care of children with medical complexity at the American Academy of Pediatrics 2025 National Conference & Exhibition. Speakers describe their study findings and implications for practice. Dr. Rishi Agrawal discusses the role of the Council on Children with Disabilities in translating research into improved clinical care and advocacy for children with medical complexity. SPEAKERS Rishi Agrawal, MD, MPH Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Attending Physician, Ann & Robert H. Lurie Children's Hospital of Chicago Elizabeth Avery ‌Hill, DO Assistant Professor, University of Utah‌ Michelle Melicosta, MD, MPH, MSC, Associate Chief Medical Officer, Kennedy Krieger Institute, Assistant Professor, Johns Hopkins University School of Medicine Patricia Notario, MD, Medical Director of the Pediatric Complex Care Program, Billings Clinic Prasiddha Parthasarathy, MD, Resident, University of Toronto HOSTS Kristina Malik, MD Assistant Professor of Pediatrics, University of Colorado School of Medicine Medical Director, KidStreet Pediatrician, Special Care Clinic, Children's Hospital Colorado Kilby Mann, MD Assistant Professor Pediatric Rehabilitation Medicine Children's Hospital Colorado Kathleen Huth, MD, MMSc Pediatrician, Complex Care Service, Division of General Pediatrics Boston Children's Hospital Assistant Professor of Pediatrics Harvard Medical School DATE Initial publication date: October 14, 2025. RESOURCES REFERENCED ‌Project ECHO/ECHO Model: https://projectecho.unm.edu/model/ ‌Council on Children with Disabilities (COCWD): https://www.aap.org/en/community/aap-councils/council-on-children-with-disabilities/ ‌AAP Experience National Conference Denver 2025 - Conference Schedule: https://aapexperience.org/schedule/ TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/m48sjfwmqfnrfwnxg8p7p88/CCJCP_2025_AAP_conference_10-13-25.pdf Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6. Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Mann K, Malik K, Agrawal R, Hill EA, Melicosta M, Notario P, Parthasarathy P, Huth K. Practice-Changing Research in Complex Care at the American Academy of Pediatrics Conference 2025. 10/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/practice-changing-research-in-complex-care-at-the-american-academy-of-pediatrics-conference-2025.

Show Notes: Scott Cole describes his initial struggles at Harvard, dropping out after freshman year, and returning multiple times before finally graduating in 2012. He  shares his first dropout experience, including a brief stint in California and a return to Harvard for sophomore year. He details his various jobs and adventures, including working at a car wash, landscaping, and a research assistant position at Harvard Forest. Working on a Ranch in Wyoming Scott thinks back to his days working at a ranch in Wyoming, where he learned cowboy skills and participated in cattle drives. He describes his move to Middlebury, Vermont, where he worked on an organic farm, a cross-country ski area, and a bakery. He also shares where he learned to cook. Back to School and on to a Law firm Scott discusses his return to Boston to finish college, working part-time at a law firm and attending school. He describes the challenges of balancing work, school, and financial aid, leading to another dropout. Scott talks about his relationship ending and moving back to California, where he worked at Sequoia National Park resort teaching cross country skiing. He quit this job to go to Guatemala with his dad's school group and spent some time there before moving to Oakhurst and working at a restaurant where he learned cooking skills. He worked there for two years until he paid off his student loans, and with his new found freedom, decided to hit the road and hike through the Sierra Mountains. He also talks about working in Fresno and in a job at the UC Cooperative Extension promoting school gardening as a way to teach nutrition education. From Alaska to Nevada Scott recounts his time working at a ranch in Alaska, teaching cross-country skiing, and working as a hiking guide and naturalist. He later moved to Boston to help a friend renovate a Victorian house and then worked with the Boston Children's Museum. After Boston, Scott describes his move to Michigan to be with a girlfriend in graduate school and working at the Maharishi Vedic University in their organic greenhouse. He also talks about his work with the Nevada Conservation Corps, cooking for a chainsaw crew, and his job at the White Mountain Research Station where he looked after a herd of sheep and cooked for the researchers. Scott finally decided to return to Harvard to finish his last six classes and talks about his experience completing his degree. Riding the Wave After completing his degree, Scott biked across the country with a friend. He reflects on his diverse experiences, including working with his hands, helping a friend who is a sculptor on building a sculpture for an exhibit. He talks about “The Table” tour working in Death Valley, and volunteering at various places, and biking in Canada from the Rockies to Bella Coola. He discusses the challenges of returning to school at an older age and the joy of completing his degree. Scott mentions his love for gardening, cooking, music, hiking, and outdoor activities, and how these hobbies filled his off-hours. Harvard Reflections An English major at Harvard, Scott mentions seeing Alan Ginsberg read at Harvard. He mentions taking a poetry class and a printing class. He also mentions Literature and Human Suffering with James Engell, Chicano Literature with visiting UCLA professor Héctor Calderón, Folklore and Mythology with Simon Bronner, a poetry class with Henri Cole, and Place, Space, and Region with Stephanie Burt.  Timestamps:  00:02: Scott Cole's Journey through Harvard and Beyond  06:36: Exploring Different Career Paths  09:41: Returning to School and Balancing Work and Education 40:07: Adventures in Alaska and Beyond  54:13: Reflecting on Life Experiences and Future Plans Links: Instagram: scootersride  Historical building preservation: Welcome to HistoriCorps - HistoriCorps Adobe restoration: cstones.orghttps://www.cstones.orgCornerstones Community  Adobe courses and home builder support:  Adobe in Actionhttps://www.adobeinaction.orgAdobe in Action Reuben Margolin art: Waves – Reuben Margolin – Kinetic Artist Science Research Station: White Mountain Research Center — Supporting scientific achievement for 75 years. Featured Non-profit: The featured non-profit of this week's episode is brought to you by Jared Eigerman who reports: “Hi. I'm Jay Eigerman, class of 1992. The featured nonprofit of this episode of The 92 Report is Street Lab. Street Lab is a nonprofit that works in neighborhoods throughout New York City to activate and improve spaces, including pedestrian streets, at no cost to the public. I've been a board member since 2011 when they first started in Boston. I especially like the street lab sales programming kits at reasonable cost so others around the world can deploy them on their own. Please take a look at streetlab.org. Now here is Will Bachman with this week's episode.” To learn more about their work, visit: streetlab.org.

In this podcast, JPEN Editor-in-Chief Dr. Kenneth Christopher, interviews Carly Milliren from the Biostatistics and Research Design Center at Boston Children's Hospital. Carly Milliren is a health services researcher primarily in pediatrics with a specific focus on eating disorders. Carly Milliren is first author of the research article “Identifying enteral nutrition using administrative data in pediatrics patients with eating disorders: A development and validation study”. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US October 2025

Is the "best" hospital just about technology and surgical success? Ben Harder, the journalist who oversees the methodology and data for the U.S. News Best Children's Hospitals Rankings (2025), joins Katie to break down what truly defines quality in pediatric care. Ben shares his deeply personal family story—a tragedy 50 years in the past that drives his commitment to making data-driven information accessible today. This episode is a crucial guide for parents, explaining the three core pillars of the rankings: structure/resources, processes of care, and patient outcomes. We dive into why essential human-focused services like Child Life Specialists, chaplains, and family advisory boards are included in the scorecard and how they influence the rankings. Ben illuminates the challenge faced by these vital "cost centers" in a revenue-driven healthcare system, and offers a powerful message: parents are the strongest possible advocates for their children, and they should use every resource available—including the U.S. News data—to make informed, collaborative choices for their child's care team. Guest Links U.S. News Best Children's Hospitals Rankings: All data is freely available for families to research hospitals by region and specialty. Website: US News Press Release Episode Highlights & Key Takeaways The Personal Motivation: Ben shares the heartbreaking story of his cousin, whose permanent brain injury after a heart surgery complication 50 years ago lacked the complete care team needed to ensure a good outcome—a void the U.S. News data is designed to fill today. The Three Pillars of Ranking: US News analyzes over 1,000 data points grouped into: 1) Resources/Structure (nurses, expertise, technology, child life services), 2) Processes of Care (following best practices, infection control), and 3) Outcomes (survival, length of stay, quality of life). The Honor Roll: The 2025 Honor Roll features the top 10 hospitals recognized for high performance across multiple specialties, including: Boston Children's Hospital, The Children's Hospital of Philadelphia (CHOP), Cincinnati Children's, Texas Children's Hospital, and others. A Piece of the Puzzle: The rankings are one resource to use alongside insurance coverage, geographic location, and most importantly, consulting your child's doctors and trusting your parental intuition. The Value of Human Support: Services like Child Life Specialists, support groups, and family advisory boards are included in the structural data points, serving as a motivator for hospitals to invest in comprehensive, family-centered care. Advocacy is Essential: Ben gives parents permission to advocate relentlessly, reminding them they know their child best. Collaborating with—not simply questioning—the care team can be life-saving. Chapters: Timestamp Topic 0:00 Ben Harder's Personal Connection to Hospital Rankings 1:03 The Official Launch of the U.S. News Best Children's Hospitals 2025 3:20 US News Honor Roll: The Top 10 Children's Hospitals 4:26 FREE COURSE Ad: Shots, Blood Draws & Comfort Positioning 5:35 Meet Ben Harder: Journalist, Father, and Best Hospitals Lead 7:59 The 3 Pillars of US News Ranking Methodology (1000+ Data Points) 11:37 The Role of Expert Work Groups in Defining Data 13:58 The Future of Family Expertise in Shaping Rankings 16:59 How Families Should Use the U.S. News Rankings 21:09 Why Child Life Services and Support Resources Matter in Rankings 25:12 Why Support Services are Overlooked: Revenue vs. Cost Centers 27:54 Ben Harder's Personal Story: The Tragic Need for Comprehensive Care 31:00 The Efficacy and Impact of Child Life Specialists 34:36 What Families Should Expect and Ask For: Advocacy Permission 38:23 Where to Find the U.S. News Best Children's Hospitals Rankings 38:58 Disclaimer   Resources for You 1. Unlock Two FREE Courses (Value $250+) We want to equip you to better support your child during medical experiences! Get our popular courses "How to Prepare, Support, and Respond to Your Child During Shots, Blood Draws, and Vaccines" AND "How to Use Comfort Positioning in Pediatrics" completely free. How to Get It: Leave a written review for the Child Life On Call podcast on Apple Podcasts or Spotify. Take a quick screenshot of your submitted review. Email the screenshot to: podcast@childlifeoncall.com 2. Connect with Child Life On Call Website: ChildLifeOnCall.com Instagram: @ChildLifeOnCall Disclaimer: The content of this podcast is for informational purposes only. The host and guests are not licensed therapists or medical doctors. Always consult with your child's qualified medical professional for advice specific to your family's situation.  

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

All about gymnastics! We interview Dr. Elspeth Hart from Boston Children's on her latest article on Gymnastics Medicine and what to look out for when treating gymnasts in the orthopedic setting. We also highlight recent articles on the urgency of stable SCFE, a lesser-known method for pinning supracondylar humerus fractures, and short versus long leg casting for distal tibia physeal fractures. Your hosts are Tyler McDonald (University of South Alabama), and Stephanie Logterman (Arnold Palmer Hospital for Children), Josh Holt (University of Iowa), and Carter Clement (Manning Family Children's in New Orleans). Music by A. A. Aalto. Gymnastics Upper Extremity Article mentioned: Hart E, Bauer AS, Bae DS. Common upper extremity gymnastics injuries and gymnastic specific return to play protocols. J Pediatr Soc North Am. 2024 Feb 28;6:100016. doi: 10.1016/j.jposna.2024.100016. PMID: 40433250; PMCID: PMC12088353. Link to the non profit Gymnastics Medicine: Education and Research: GymnasticsMedicine.org Link to learn more about the 7th annual Gymnastics Medicine Symposium (use code "Gym15" to save 15% if interested in signing up!): Symposium 2025 - Gymnastics Medicine   References: 1. Hart E, Bair K, Broz J, Griffith K, Herrera-Set A, Lattimore D, Melvin E, Sweeney E. Gymnastics Medicine: A New Subspecialty in Sports Medicine. Curr Sports Med Rep. 2025 May 1;24(5):126-134. doi: 10.1249/JSR.0000000000001249. PMID: 40323057. 2. White AB, Keil LG, Bardsley H, Selberg C, Mansour A, Brooks AC, Manickam R, Mayassi HA, Zhao L, Uchtman M, Whitlock P, Stone J. How Urgent Are Stable SCFEs? A Multisite Retrospective Study of Surgical Timing and Complications Among Patients With Stable Slipped Capital Femoral Epiphysis. J Pediatr Orthop. 2025 Sep 1;45(8):485-491. doi: 10.1097/BPO.0000000000002997. Epub 2025 May 1. PMID: 40314216. 3. Grewal RS, Kitchen BT, Bomar JD, Cidambi EO, Dexter MJ, Edmonds EW, Pring ME, Upasani VV, Wallace CD, Pennock A. Displaced Distal Tibia Physeal Fractures: Short Leg Versus Long Leg Casting-A Prospective Study. J Pediatr Orthop. 2025 Aug 1;45(7):e614-e617. doi: 10.1097/BPO.0000000000002961. Epub 2025 Apr 7. PMID: 40191914. 4. Muto S, Niwa S, Fujihara Y, Ota H, Kumagai H. Comparative Analysis of Postoperative Rotational Malalignment in Pediatric Supracondylar Humerus Fractures: Cross Pinning Versus Lateral Para-olecranon Pinning. J Pediatr Orthop. 2025 Sep 1;45(8):458-465. doi: 10.1097/BPO.0000000000003000. Epub 2025 May 5. PMID: 40323798.

In this episode, Dr. Robert Insoft, Neonatologist and Chief Operating Officer at Franciscan Children's Campus, Boston Children's Hospital System, shares his perspective on guiding teams through healthcare integrations, prioritizing staff engagement, and evolving as a leader to ensure high quality patient care.

A bonus episode in our series "Falling Behind: The Miseducation of America's Boys." Dr. Kevin Simon, attending pediatric psychiatrist at Boston Children's Hospital, shares his experience and expertise in a conversation recorded on stage at WBUR CitySpace.